New cancer vaccine combo aims to outperform standard treatment in major trial
Disease control
Ongoing
This large, late-stage trial is testing whether adding an experimental immunotherapy called PDS0101 to the standard drug pembrolizumab (Keytruda) helps people with advanced HPV-positive head and neck cancer live longer. The study will enroll about 351 adults whose cancer has retu…
Phase: PHASE3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC